PMID- 20188504
OWN - NLM
STAT- MEDLINE
DCOM- 20100617
LR  - 20220321
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 55
IP  - 20
DP  - 2010 May 18
TI  - Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in 
      heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging 
      for Risk Evaluation in Heart Failure) study.
PG  - 2212-21
LID - 10.1016/j.jacc.2010.01.014 [doi]
AB  - OBJECTIVES: The ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in 
      Heart Failure) study prospectively evaluated iodine-123 meta-iodobenzylguanidine 
      ((123)I-mIBG) imaging for identifying symptomatic heart failure (HF) patients 
      most likely to experience cardiac events. BACKGROUND: Single-center studies have 
      demonstrated the poorer prognosis of HF patients with reduced (123)I-mIBG 
      myocardial uptake, but these observations have not been validated in large 
      multicenter trials. METHODS: A total of 961 subjects with New York Heart 
      Association (NYHA) functional class II/III HF and left ventricular ejection 
      fraction (LVEF) < or =35% were studied. Subjects underwent (123)I-mIBG myocardial 
      imaging (sympathetic neuronal integrity quantified as the heart/mediastinum 
      uptake ratio [H/M] on 4-h delayed planar images) and myocardial perfusion imaging 
      and were then followed up for up to 2 years. Time to first occurrence of NYHA 
      functional class progression, potentially life-threatening arrhythmic event, or 
      cardiac death was compared with H/M (either in relation to estimated lower limit 
      of normal [1.60] or as a continuous variable) using Cox proportional hazards 
      regression. Multivariable analyses using clinical, laboratory, and imaging data 
      were also performed. RESULTS: A total of 237 subjects (25%) experienced events 
      (median follow-up 17 months). The hazard ratio for H/M > or =1.60 was 0.40 (p < 
      0.001); the hazard ratio for continuous H/M was 0.22 (p < 0.001). Two-year event 
      rate was 15% for H/M > or =1.60 and 37% for H/M <1.60; hazard ratios for 
      individual event categories were as follows: HF progression, 0.49 (p = 0.002); 
      arrhythmic events, 0.37 (p = 0.02); and cardiac death, 0.14 (p = 0.006). 
      Significant contributors to the multivariable model were H/M, LVEF, B-type 
      natriuretic peptide, and NYHA functional class. (123)I-mIBG imaging also provided 
      additional discrimination in analyses of interactions between B-type natriuretic 
      peptide, LVEF, and H/M. CONCLUSIONS: ADMIRE-HF provides prospective validation of 
      the independent prognostic value of (123)I-mIBG scintigraphy in assessment of 
      patients with HF. (Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With 
      Heart Failure and Control Subjects Without Cardiovascular Disease, NCT00126425; 
      Meta-Iodobenzylguanidine [123I-mIBG] Scintigraphy Imaging in Patients With Heart 
      Failure and Control Subjects Without Cardiovascular Disease, NCT00126438).
FAU - Jacobson, Arnold F
AU  - Jacobson AF
AD  - GE Healthcare, Princeton, New Jersey, USA.
FAU - Senior, Roxy
AU  - Senior R
FAU - Cerqueira, Manuel D
AU  - Cerqueira MD
FAU - Wong, Nathan D
AU  - Wong ND
FAU - Thomas, Gregory S
AU  - Thomas GS
FAU - Lopez, Victor A
AU  - Lopez VA
FAU - Agostini, Denis
AU  - Agostini D
FAU - Weiland, Fred
AU  - Weiland F
FAU - Chandna, Harish
AU  - Chandna H
FAU - Narula, Jagat
AU  - Narula J
CN  - ADMIRE-HF Investigators
LA  - eng
SI  - ClinicalTrials.gov/NCT00126425
SI  - ClinicalTrials.gov/NCT00126438
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20100225
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Iodine Radioisotopes)
RN  - 0 (Radiopharmaceuticals)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 35MRW7B4AD (3-Iodobenzylguanidine)
SB  - IM
CIN - J Am Coll Cardiol. 2010 May 18;55(20):2222-4. PMID: 20466202
MH  - *3-Iodobenzylguanidine
MH  - Aged
MH  - Disease Progression
MH  - Female
MH  - Heart/diagnostic imaging
MH  - Heart Failure/*diagnostic imaging
MH  - Humans
MH  - Iodine Radioisotopes
MH  - Male
MH  - Mediastinum/diagnostic imaging
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Prospective Studies
MH  - *Radiopharmaceuticals
MH  - Research Design
MH  - Risk Assessment
MH  - Stroke Volume
MH  - Tomography, Emission-Computed, Single-Photon/statistics & numerical data
MH  - Ventricular Dysfunction, Left/*diagnostic imaging
EDAT- 2010/03/02 06:00
MHDA- 2010/06/18 06:00
CRDT- 2010/03/02 06:00
PHST- 2009/08/17 00:00 [received]
PHST- 2010/01/19 00:00 [revised]
PHST- 2010/01/20 00:00 [accepted]
PHST- 2010/03/02 06:00 [entrez]
PHST- 2010/03/02 06:00 [pubmed]
PHST- 2010/06/18 06:00 [medline]
AID - S0735-1097(10)00395-5 [pii]
AID - 10.1016/j.jacc.2010.01.014 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2010 May 18;55(20):2212-21. doi: 10.1016/j.jacc.2010.01.014. 
      Epub 2010 Feb 25.